An Umbrella Review of Effectiveness of Intravenous Ketamine in Treatment-Resistant Depression
European Psychiatry April 1, 2024 Amanda M. Klassen, Caitlin Baten, J. H. Shepherd et al.
Introduction Major depressive disorder (MDD) is a tremendous global disease burden and the leading cause of disability worldwide. Unfortunately, individuals diagnosed with MDD typically experience a delayed response to traditional antidepressants and many do not adequately respond to pharmacotherapy, even after multiple trials. The critical need for novel antidepressant treatments has led to a...